Savior Lifetec Corporation (TPEX:4167)

Market Cap	6.27B
Revenue (ttm)	1.16B
Net Income (ttm)	495.76M
Shares Out	310.44M
EPS (ttm)	1.57
PE Ratio	12.90
Forward PE	n/a
Dividend	0.40 (1.94%)
Ex-Dividend Date	Jul 14, 2025

Volume	40,000
Average Volume	2,166,695
Open	20.45
Previous Close	20.20
Day's Range	19.95 - 20.45
52-Week Range	14.35 - 22.10
Beta	0.26
RSI	67.44
Earnings Date	Mar 13, 2026

About Savior Lifetec

Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, meropenem, and ertapenem products. The company was founded in 1993 and is headquartered in Tainan, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 384
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4167

Financial Performance

In 2024, Savior Lifetec's revenue was 1.22 billion, an increase of 15.91% compared to the previous year's 1.05 billion. Earnings were 182.38 million, an increase of 507.33%.